Kuratiert · Gesundheit

Big pharma

Von InspectStocksPublished 14. Okt. 202613 companies0 followers

The largest drugmakers, selling prescription medicines worldwide.

Mit Hilfe eines KI-Modells gruppiert und von unserer Redaktion geprüft. Die Zeile unter jedem Unternehmen sagt, warum es hier steht.

Download image

Karten Stufen

Aktienkurse sind die Schlusskurse vom 11. Nov. 2026, aus dem IEX-Börsenfeed.

Grade mix

A 7B 3C 3

Revenue growing

12 of 12

Free cash flow growing

9 of 13

Median price move, 1 year

+34,0 %

Sort by

LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap 1,35T $P/E 46,67
1.437,79 $+42,2 %1Y
Since added +23,2 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
86,5B $+45,5 %
Profit
27,6B $+49,8 %
Free cash flow
19,7B $+112,1 %
Discuss
Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
JNJJohnson & Johnson
Drug manufacturers generalMarket cap 674,9B $P/E 42,54
280,34 $+47,5 %1Y
Since added +12,8 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Gemischt
Revenue
99,3B $+7,8 %
Profit
16,1B $-35,9 %
Free cash flow
20,6B $+5,1 %
Discuss
Why it is here: Sells prescription medicines for cancer and immune disorders
ABBVAbbVie Inc.
Drug manufacturers generalMarket cap 521,2B $P/E 50,75
294,87 $+30,2 %1Y
Since added +7,5 %
B+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
66B $+10,7 %
Profit
10,3B $+333,1 %
Free cash flow
18,9B $-4,1 %
Discuss
Why it is here: Sells medicines for immune, neurological and cancer conditions
MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap 362,9B $P/E 150,20
147,20 $+65,7 %1Y
Since added +3,7 %
A
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Solide
Getting better
Gemischt
Revenue
67,4B $+4,9 %
Profit
2,5B $-87,1 %
Free cash flow
14,7B $+13,0 %
Discuss
Why it is here: Sells prescription medicines and vaccines for people and animals
NVSNovartis AG
Drug manufacturers generalMarket cap 306B $Kein KGV (operativer Verlust)
160,36 $+23,6 %1Y
Since added +12,6 %
A
Wachstum und Cash
Wächst kräftig
Business quality
Gemischt
Getting better
Verbessert sich deutlich
Revenue
56,7B $+9,6 %
Profit
-46M $No comparable year
Free cash flow
17,6B $+8,3 %
Discuss
Why it is here: Sells prescription medicines
AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap 289,7B $P/E 28,36
185,49 $+115,2 %1Y
Since added +19,0 %
B+
Wachstum und Cash
Wächst kräftig
Business trend
Verlangsamt
Business quality
Stark
Getting better
Verbessert sich deutlich
Revenue
62,4B $+7,3 %
Profit
10,2B $+45,3 %
Free cash flow
11,8B $+18,4 %
Discuss
Why it is here: Sells prescription medicines
NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap 182,8B $P/E 11,84
41,10 $-15,4 %1Y
Since added +8,0 %
C+
Wachstum und Cash
Wächst
Business trend
Beschleunigt
Business quality
Stark
Getting better
Verbessert sich
Revenue
50,3B $+5,7 %
Profit
17,1B $+9,1 %
Free cash flow
8,9B $-20,1 %
Discuss
Why it is here: Sells diabetes and obesity medicines
PFEPFIZER INC
Drug manufacturers generalMarket cap 167,9B $P/E 42,07
29,45 $+21,4 %1Y
Since added +3,8 %
C
Wachstum und Cash
Wächst kräftig
Business trend
Schrumpfend
Business quality
Solide
Getting better
Gemischt
Revenue
63,6B $+1,3 %
Profit
4B $-59,0 %
Free cash flow
11,8B $+13,6 %
Discuss
Why it is here: Sells prescription medicines and vaccines
BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap 128,6B $P/E 13,95
62,92 $+34,0 %1Y
Since added +11,0 %
C+
Wachstum und Cash
Wächst
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich deutlich
Revenue
50B $+4,2 %
Profit
9,2B $+53,1 %
Free cash flow
9,3B $-39,3 %
Discuss
Why it is here: Sells prescription medicines for cancer and immune conditions
SNYSanofi
Drug manufacturers generalMarket cap 59,1B $P/E 6,81
48,43 $-3,0 %1Y
Since added +23,9 %
B
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Gemischt
Getting better
Verbessert sich
Revenue
53,5B $+11,6 %
Profit
4,7B $-54,2 %
Free cash flow
8,1B $+22,5 %
Discuss
Why it is here: Sells prescription medicines and vaccines
GSKGSK plc
Drug manufacturers generalMarket cap 109,2B $P/E 13,60
50,60 $+8,9 %1Y
Since added +9,3 %
A+
Wachstum und Cash
Wächst kräftig
Business quality
Stark
Getting better
Verbessert sich deutlich
Revenue
43,8B $+4,1 %
Profit
7,7B $+122,0 %
Free cash flow
8,6B $+24,0 %
Discuss
Why it is here: Sells prescription medicines and vaccines worldwide
AMGNAmgen Inc.
Drug manufacturers generalMarket cap 253,2B $P/E 27,14
468,13 $+43,1 %1Y
Since added +13,4 %
A+
Wachstum und Cash
Wächst kräftig
Business trend
Stabil
Business quality
Stark
Getting better
Verbessert sich
Revenue
38,9B $+8,2 %
Profit
9,4B $+34,1 %
Free cash flow
9,6B $-17,0 %
Discuss
Why it is here: Develops and sells medicines and biosimilars for serious diseases
TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap 33,5B $P/E 48,79
20,86 $+50,1 %1Y
Since added +12,5 %
A
Wachstum und Cash
Wächst kräftig
Business quality
Gemischt
Getting better
Gemischt
Revenue
29,8B $No comparable year
Profit
259,4M $No comparable year
Free cash flow
5,5B $+1,1 %
Discuss
Why it is here: Sells prescription medicines and vaccines globally

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.